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Abstract
Introduction Acute lung injury often complicates severe sepsis.
In Gram-negative sepsis, bacterial endotoxin activates both
coagulation and inflammation. Enhanced lung vascular
pressures and permeability, increased extravascular lung water
content and deteriorated gas exchange characterize ovine
endotoxin-induced lung injury, a frequently used model of acute
lung injury. Recombinant human activated protein C (rhAPC),
with its anticoagulant, anti-inflammatory, fibrinolytic and
antiapoptotic effects, reportedly reduces the respirator-
dependent days and the mortality of patients with severe sepsis.
We speculate whether rhAPC antagonizes endotoxin-induced
lung injury in sheep.
Methods Two groups of sheep were exposed to Escherichia
coli  endotoxin (lipopolysaccharide) 15 ng/kg/minute
intravenously from 0 to 24 hours; one group received only
lipopolysaccharide throughout (n = 8), and the other group
received lipopolysaccharide in combination with rhAPC 24 μg/
kg/hour from 4 to 24 hours (n = 9). In addition, one group
received rhAPC as above as the only intervention (n = 4), and
four sham-operated sheep were used for determination of the α
and ε isoforms of protein kinase C in pulmonary tissue. Data
were assessed by one-way analysis of variance for repeated
measurements. Biochemical data were analyzed using
Student's  t  test, or using the Mann–Whitney U test when
appropriate.
Results Infusion of endotoxin caused lung injury, manifested by
increments in pulmonary artery pressure, in pulmonary micro-
occlusion pressure, in pulmonary vascular downstream
resistance, in pulmonary vascular permeability index, in
extravascular lung water index and in deterioration of
oxygenation that were all attenuated by infusion of rhAPC.
Endotoxemia led to changes in inflammation and coagulation,
including pulmonary neutrophil accumulation paralleled by
increased TNFα and decreased protein C and fibrinogen in
animal plasma, which all improved following infusion of rhAPC.
Moreover, rhAPC prevented the translocation of protein kinase
C α and ε isoforms from the cytosolic fraction of lung tissue
extracts.
Conclusion In awake sheep, rhAPC alleviates endotoxin-
induced lung injury – as characterized by improvements of
oxygenation, coagulation and inflammation, as well as by
reversal of pulmonary hemodynamic and volumetric changes.
AaO2 = alveolar-arterial oxygen tension difference; ALI = acute lung injury; APC = activated protein C; CI = cardiac index; EVLWI = extravascular 
lung water index; H&E = hematoxylin and eosin; LAP = left atrial pressure; LPS = lipopolysaccharide; NF = nuclear factor; PaCO2 = partial tension 
of carbon dioxide in arterial blood; PaO2 = partial tension of oxygen in arterial blood; PAP = pulmonary arterial pressure; PKC = protein kinase C; 
Pmo = pulmonary capillary micro-occlusion pressure; PVPI = pulmonary vascular permeability index; PVRI = pulmonary vascular resistance index; 
PVRIdwn = pulmonary vascular downstream resistance index; PVRIup = pulmonary vascular upstream resistance index; rhAPC = recombinant human 
activated protein C; TNF = tumor necrosis factor.Critical Care    Vol 12 No 4    Waerhaug et al.
Page 2 of 13
(page number not for citation purposes)
Introduction
Acute lung injury (ALI) is one of the most frequent organ dys-
functions evolving from severe sepsis [1]. In Gram-negative
sepsis, endotoxin (lipopolysaccharide (LPS)) released from
bacteria stimulates transcriptional factors to activate the
inflammation and coagulation systems [2]. Proinflammatory
cytokines, tissue factor, eicosanoids and endothelins act in
concert to promote the disintegration of lung endothelial and
epithelial barriers that characterize ALI [3-7]. Recent research
has revealed that thrombin, a blood coagulation protease, is a
key trigger of both the coagulation and the inflammation sys-
tem in ALI [8].
Protein C is an inactive precursor of the serine protease acti-
vated protein C (APC), which is catalyzed by the action of
thrombin/thrombomodulin complex when protein C is bound
to its endothelial receptor (endothelial cell protein C receptor).
Acting together with protein S, APC precludes generation of
thrombin in a negative feedback loop by proteolytic cleavage
of activated factors V and VIII. APC also escalates fibrinolysis
by inhibiting plasminogen activator inhibitor 1 and thrombin-
activatable fibrinolysis inhibitor [9]. Activated protein C atten-
uates inflammation by inhibiting translocation of NF-κB and of
activator protein-1 in LPS-stimulated monocytes, thereby sup-
pressing release of proinflammatory cytokines [10,11]. More-
over, APC decreases leukocyte rolling and adhesion to the
endothelium by suppressing adhesion molecules, causing
reduced migration and accumulation of leukocytes in the air
spaces [10-13]. Investigators showed recently that cleavage
of the protease-activated receptor-1 by the APC-endothelial
cell protein C receptor complex exerts antiapoptotic and
enhanced barrier-protective effects in endothelial cells via
transactivation of the sphingosine-1-phosphate receptor
[14,15].
In sepsis and ALI both the production and the activation of pro-
tein C decrease because of extended endothelial damage
[16]. Elevation of the plasma concentration of protein C, which
normally occurs upon activation of the coagulation system, is
hence reversed with depletion of protein C and APC in septic
states. Investigators reported recently that infusion of recom-
binant human activated protein C (rhAPC) enhances the
plasma concentration of protein C and lowers the mortality
rate of patients with severe sepsis, simultaneously reducing
circulatory dysfunction and respirator-dependent days
[17,18]. Although many effects of APC on coagulation and
inflammation are well established [9,19], those effects dealing
specifically with respiratory functions have been sparsely
investigated [20,21]. Whether APC protects efficiently
against ALI in human sepsis and in animals exposed to endo-
toxin is therefore still undetermined.
In sheep, LPS enhances lung microvascular pressure and per-
meability, thereby increasing the extravascular lung water con-
tent and deteriorating gas exchange [22-25], which is
consistent with most signs of ALI in humans [26]. Activation of
inflammatory mediators and coagulation factors accompanies
the changes in pulmonary hemodynamics and gas exchange
[5-7,20,24,25,27]. We speculated whether rhAPC, given its
anti-inflammatory and anticoagulation properties, would antag-
onize these changes. Our aim was to investigate the effects of
rhAPC on sustained LPS-induced ALI in sheep over 24 hours
by assessing changes in pulmonary hemodynamics, in
extravascular lung water content, in pulmonary vascular per-
meability index and in gas exchange. Moreover, we followed
alterations in selected variables of coagulation and inflamma-
tion.
Materials and methods
The Norwegian Experimental Animal Board approved the
study according to the rules and regulations of the Helsinki
Convention for Use and Care of Animals.
Animal instrumentation
Twenty-five yearling sheep weighing 44.1 ± 2.5 kg (mean ±
standard error of the mean) were instrumented under general
anesthesia. In brief, we placed introducers in the left external
jugular vein and in the ipsilateral common carotid artery, and
via a left thoracotomy we inserted a medical-grade catheter
into the left atrium, as described previously by our group [25].
After 1 week of recovery, the sheep were placed in an experi-
mental pen. A flow-directed thermal dilution catheter
(131HF7; Baxter, Irvine, CA, USA) was introduced into the
pulmonary artery and a 4-Fr fiberoptic thermistor catheter
(PV2024L; Pulsion Medical Systems, München, Germany)
was introduced into the thoracic aorta. The catheters were
connected to pressure transducers (Transpac III; Abbott,
North Chicago, IL, USA).
Measurements and samples
Measurements were performed at 4-hour intervals. The heart
rate, mean systemic arterial pressure, mean pulmonary arterial
pressure (PAP), pulmonary arterial occlusion pressure, pulmo-
nary capillary micro-occlusion pressure (Pmo), mean left atrial
pressure (LAP), and mean right atrial pressure were recorded
on a Gould 6600 signal conditioner (Gould Instruments, OH,
USA, USA), as previously reported [24,25,28]. The cardiac
index (CI), pulmonary blood volume index, intrathoracic blood
volume index, extravascular lung water index (EVLWI), and
right ventricular end-diastolic volume index were determined
with the thermal-dye dilution method (Cold Z-021; Pulsion
Medical Systems AG). Every value was calculated as a mean
of five measurements, each consisting of a 5-ml bolus of indo-
cyanine green at 0.5 mg/ml (Pulsion Medical Systems) in ice-
cold 5% glucose injected into the right atrium [24,25].
In addition, the pulmonary vascular permeability index was cal-
culated as PVPI = EVLW/PBV [29]. The pulmonary vascular
resistance index (PVRI) was calculated as PVRI = (PAP -
LAP)/CI. The pulmonary vascular upstream resistance indexAvailable online http://ccforum.com/content/12/4/R104
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Table 1
Hemodynamic variables in instrumented awake sheep
Variable Time
0 hour 1 hour 4 hours 8 hours 12 hours 16 hours 20 hours 24 hours
PVRI
(dyne/s/cm5/m2)
rhAPC 194 ± 22 192 ± 22 179 ± 38 198 ± 58 202 ± 40 193 ± 38 195 ± 33 166 ± 20
LPS 188 ± 12 810 ± 94* 359 ± 31* 252 ± 29 227 ± 21 266 ± 35 268 ± 54 248 ± 56
LPS + rhAPC 201 ± 10 847 ± 124* 392 ± 44* 215 ± 29† 224 ± 39† 209 ± 41† 229 ± 38† 210 ± 41†
PAOP (mmHg)
rhAPC 8 ± 0 8 ± 0 9 ± 0 8 ± 1 10 ± 0 9 ± 1 9 ± 1 8 ± 1
LPS 8 ± 0 18 ± 1* 12 ± 0* 12 ± 1* 12 ± 1* 12 ± 1* 13 ± 1* 11 ± 0*
LPS + rhAPC 8 ± 1 15 ± 2* 12 ± 1* 11 ± 1* 10 ± 1* 11 ± 1* 11 ± 1* 10 ± 1
RAP (mmHg)
rhAPC 3 ± 0 3 ± 1 6 ± 1* 5 ± 1* 5 ± 1 5 ± 1* 5 ± 0* 5 ± 1
LPS 4 ± 1 5 ± 1 7 ± 1* 7 ± 2 7 ± 1* 7 ± 1* 8 ± 1* 8 ± 1*
LPS + rhAPC 3 ± 1 2 ± 1 6 ± 1* 5 ± 1* 6 ± 1* 6 ± 1* 6 ± 2* 5 ± 2
Heart rate 
(beats/min)
rhAPC 94 ± 8 91 ± 8 95 ± 6 92 ± 7 95 ± 4 97 ± 5 97 ± 6 92 ± 7
LPS 106 ± 4 139 ± 14 129 ± 7 151 ± 9 134 ± 8 127 ± 7 142 ± 12 137 ± 11
LPS + rhAPC 94 ± 5 158 ± 16* 112 ± 9* 151 ± 10* † 138 ± 11* † 128 ± 12* 122 ± 13 123 ± 12
MAP (mmHg)
rhAPC 103 ± 3 100 ± 4 103 ± 3 106 ± 5 106 ± 2 101 ± 3 105 ± 1 100 ± 5
LPS 101 ± 3 107 ± 5 110 ± 3* 90 ± 3* † 88 ± 4* † 93 ± 3† 91 ± 3* † 90 ± 3* †
LPS + rhAPC 101 ± 3 105 ± 4 108 ± 2 95 ± 4 95 ± 4 96 ± 5 95 ± 4 98 ± 5
SVRI
(dyne/s/cm5/m2)
rhAPC 1677 ± 70 1688 ± 82 1610 ± 108 1877 ± 327 1918 ± 302 1680 ± 204 1872 ± 186 1671 ± 268
LPS 1587 ± 69 1976 ± 165* 1962 ± 90* 1212 ± 87* † 1089 ± 82* † 1278 ± 101* † 1267 ± 139* † 1194 ± 111* †
LPS + rhAPC 1559 ± 68 1789 ± 153 1910 ± 107* 1302 ± 153† 1226 ± 121† 1268 ± 119† 1337 ± 141† 1367 ± 135†
Cardiac index
(l/min/m2)
rhAPC 5.4 ± 0.6 5.3 ± 0.7 5.2 ± 0.4 5.0 ± 0.8 5.0 ± 0.7 5.2 ± 0.6 4.9 ± 0.6 5.1 ± 0.6
LPS 5.3 ± 0.3 5.0 ± 0.7 4.3 ± 0.2* 6.0 ± 0.5† 6.0 ± 0.2† 5.7 ± 0.3† 5.9 ± 0.5† 6.0 ± 0.5†
LPS + rhAPC 5.1 ± 0.3 4.9 ± 0.4 4.3 ± 0.2 5.8 ± 0.3† 6.1 ± 0.4† 5.9 ± 0.4† 5.7 ± 0.5† 5.8 ± 0.5†
SVI (ml/beat/m2)
rhAPC 57 ± 3 57 ± 2 55 ± 2 54 ± 6 52 ± 7 55 ± 7 52 ± 8 57 ± 8
LPS 49 ± 2 36 ± 2* 33 ± 2* 40 ± 4 46 ± 3 45 ± 2 44 ± 5 46 ± 4
LPS + rhAPC 55 ± 2 33 ± 4* 40 ± 3* 39 ± 3* 46 ± 4* 49 ± 5 50† ± 5 49 ± 5
LAP (mmHg)
rhAPC 5 ± 1 5 ± 1 6 ± 2 6 ± 1 6 ± 1 6 ± 1 6 ± 1 7 ± 1
LPS 5 ± 1 5 ± 1 8 ± 1* 8 ± 1* 8 ± 1* 9 ± 1* 9 ± 1* 9 ± 1*Critical Care    Vol 12 No 4    Waerhaug et al.
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(PVRIup = (PAP - Pmo)/CI) and the pulmonary vascular down-
stream resistance index (PVRIdwn = (Pmo - LAP)/CI) were also
determined. The systemic vascular resistance index, the stroke
volume index, the left and right ventricular stroke work indices,
and the right ventricular ejection fraction were calculated
using standard formulas provided by the Cold Z-021.
Blood samples were drawn from systemic and pulmonary
artery lines, and were analyzed for blood gases and hemo-
globin (Rapid 860; Chiron Diagnostics Corporation, East Wal-
pole, MA, USA). The alveolar–arterial oxygen tension
difference, the oxygen delivery index, the oxygen consumption
index, and the venous admixture were calculated as described
previously [25]. Plasma concentrations of TNF1α were deter-
mined with an Immulite instrument using a commercially avail-
able kit (Diagnostic Products Corporation, Los Angeles, CA,
USA). Protein C levels and antithrombin III levels were both
determined by commercially available kits using chromogenic
substrates (STA-STACHROM®; Diagnostica Stago, Asnieres,
France). The International Normalized Ratio determined factor
II, factor VII and factor X combined by the measuring clotting
time (prothrombin time) in the presence of tissue thromboplas-
tin. All factors were present in excess, except for factors II, VII
and X, all derived from the plasma being tested. Fibrinogen
was determined with a modified Clauss method using rea-
gents and an instrument (STA-R) from Diagnostica Stago
according to the instructions of the manufacturer.
Experimental protocol
Sheep were randomly assigned to three groups: the rhAPC
group (n = 4) received an intravenous infusion of 24 μg/kg/
hour drotrecogin-alpha (Xigris; Eli Lilly & Co., Indianapolis, IN,
USA) from 4 to 24 hours; the LPS group (n = 8) received an
intravenous infusion of Escherichia coli O26:B6 endotoxin
(LPS) (Sigma Chemical, St Louis, MO, USA) at 15 ng/kg/
minute from 0 to 24 hours; and the LPS + rhAPC group (n =
9) received LPS and rhAPC at the same doses as above. In
addition, four sham-operated sheep were used only for detec-
tion of protein kinase C (PKC) in lung tissue. All sheep had an
infusion of isotonic saline at 3 ml/kg/hour throughout the
experiment. After completion of the experiment, euthanasia
was performed with an intravenous injection of 100 mg/kg
pentobarbital (Pentobarbital NAF; Ås Production Lab, Ås, Nor-
way) followed by 50 mmol KCl. Lung biopsies from all lobes
were frozen in liquid nitrogen for later determination of the α
and ε isoforms of PKC by western blotting and for histological
examination.
Western blotting
The protein extraction, fractionation and detection procedure
is described in detail elsewhere [24]. Briefly, lung tissue was
homogenized and, after centrifugation at 100,000 × g for 60
minutes at 4°C, the supernatant (cytosolic fraction) was col-
lected and used for western blotting using rabbit polyclonal
antibodies against PKC isoenzymes α and ε (SC-208 and SC-
214, respectively; Santa Cruz Biotech., Santa Cruz, CA,
USA). Immunopositive bands were quantified by densitometry.
Lung sampling for histologic examination
Representative tissue blocks from all lung lobes were pre-
served in 4% formaldehyde, were sectioned and stained with
H&E, and were examined by light microscopy for evidence of
lung injury. The lung injury score was assessed according to
Zhou and colleagues [30]. Briefly, a pathologist without knowl-
edge of the group identity scored each section based on the
presence and the degree of edema, neutrophil sequstration,
hemorrhage, epithelial desquamation and alveolar hyaline
membranes, with zero as the lowest score and four as the
highest score, as reported previously from our group [25]. Typ-
ical photomicrographs were taken using a Leica DM 2500
microscope and a Leica DFC 320 digital camera, with the soft-
LPS + rhAPC 5 ± 1 3 ± 1 6 ± 1 9 ± 2* 8 ± 2* 9 ± 2* 8 ± 2* 9 ± 2*
LVSWI (g/m/m2)
rhAPC 67 ± 3 69 ± 4 68 ± 3 69 ± 12 62 ± 8 63 ± 11 61 ± 12 64 ± 11
LPS 62 ± 3 42 ± 3* 44 ± 2* 43 ± 4* 49 ± 5 50 ± 3* 47 ± 6* 49 ± 5*
LPS + rhAPC 69 ± 4 42 ± 6* 52 ± 4* 44 ± 3* 53 ± 4* 56 ± 5* 56 ± 5* 59 ± 7
RVSWI (g/m/m2)
rhAPC 11 ± 1 11 ± 1 9 ± 1 9 ± 1 9 ± 1 9 ± 1 9 ± 1 10 ± 2
LPS 9 ± 0 22 ± 1* 9 ± 0 11 ± 1 12 ± 1 12 ± 1* 11 ± 1 10 ± 1
LPS + rhAPC 10 ± 1 21 ± 2* 11 ± 1 9 ± 1 11 ± 1 10 ± 1 11 ± 2 11 ± 2
Data presented as the mean ± standard error of the mean. rhAPC, recombinant human activated protein C alone (n = 4); LPS, lipopolysaccharide 
group (n = 8); LPS + rhAPC, rhAPC-treated LPS group (n = 9); PVRI, pulmonary vascular resistance index; PAOP, pulmonary arterial occlusion 
pressure; RAP, right atrial pressure; MAP, mean arterial pressure; SVRI, systemic vascular resistance index; SVI, stroke volume index; LAP, left 
atrial pressure; LVSWI, left ventricle stroke work index; RVSWI, right ventricle stroke work index. *P < 0.05 from t = 0 hours. †P < 0.05 from t = 4 
hours.
Table 1 (Continued)
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ware Leica IM50 (Leica Microsystems GmbH, Wetzlar, Ger-
many).
Statistical analysis
Data are expressed as the mean ± standard error of the mean.
The Kolmogorov-Smirnov test was used to assess the data
distribution. Normally distributed data were analyzed by two-
factor analysis of variance for repeated measurements (SPSS
14.0 for Windows; LEAD Technologies, Chicago, IL, USA). To
evaluate differences within groups over time, we employed
test of contrasts. The Greenhouse–Geisser epsilon factor-
adjusted probability levels were used when Mauchly's test was
significant. For evaluation of coagulation and inflammatory
markers, a t test was employed to test for differences between
Figure 1
Changes in pulmonary vascular pressures and fluid filtration in awake, endotoxemic sheep Changes in pulmonary vascular pressures and fluid filtration in awake, endotoxemic sheep. rhAPC, recombinant human activated protein C alone 
group (n = 4); LPS, lipopolysaccharide group (n = 8); LPS + rhAPC, rhAPC-treated LPS group (n = 9). Data presented as the mean ± standard 
error of the mean. PAP, pulmonary arterial pressure; Pmo, pulmonary micro-occlusion pressure; PVRIup, upstream pulmonary vascular resistance 
index; PVRIdwn, downstream pulmonary vascular resistance index; EVLWI, extravascular lung water index; PVPI, pulmonary vascular permeability 
index. †P < 0.05 between the LPS and the LPS + rhAPC groups; ‡P < 0.05 from t = 0 hours in the LPS group; §P < 0.05 from t = 4 hours in the 
LPS group; *P < 0.05 from t = 0 hours in the LPS + rhAPC group; #P < 0.05 from t = 4 hours in the LPS + rhAPC group.Critical Care    Vol 12 No 4    Waerhaug et al.
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Table 2
Respiratory and metabolic variables in instrumented awake sheep
Time
0 hours 4 hours 8 hours 12 hours 16 hours 20 hours 24 hours
SaO2 (%)
rhAPC 96 ± 3 95 ± 3 98 ± 1 99 ± 1 98 ± 1 98 ± 1 99 ± 1
LPS 98 ± 0 98 ± 1 98 ± 1 98 ± 1 98 ± 1 97 ± 2 97 ± 2
LPS + rhAPC 98 ± 0 96 ± 1 98 ± 0 98 ± 1 97 ± 1 97 ± 1 98 ± 1
SvO2 (%)
rhAPC 61 ± 4 59 ± 4 61 ± 5 59 ± 5 61 ± 4 61 ± 5 63 ± 4
LPS 62 ± 3 62 ± 3 69 ± 2* † 67 ± 3* 64 ± 3 63 ± 3 61 ± 3
LPS + rhAPC 63 ± 3 61 ± 3 70 ± 3† 66 ± 2† 67 ± 2* † 66 ± 2 67 ± 2* †
DO2I (ml/min/m2)
rhAPC 640 ± 64 649 ± 7 626 ± 85 573 ± 63 614 ± 39 595 ± 72 654 ± 54
LPS 608 ± 32 585 ± 48 785 ± 53* 763 ± 62* 731 ± 45* 748 ± 70* 751 ± 73*
LPS + rhAPC 642 ± 52 611 ± 38 802 ± 76* † 772 ± 58† 732 ± 51† 693 ± 51 704 ± 55
VO2I (ml/min/m2)
rhAPC 225 ± 37 244 ± 26 243 ± 63 222 ± 46 215 ± 28 206 ± 12 218 ± 28
LPS 226 ± 7 207 ± 11 232 ± 15 234 ± 14 252 ± 19 261 ± 24 277 ± 30
LPS + rhAPC 229 ± 26 231 ± 22 225 ± 21 249 ± 20 232 ± 17 227 ± 19 227 ± 22
Qs/Qt
rhAPC 0.12 ± 0.06 0.13 ± 0.06 0.05 ± 0.02 0.04 ± 0.02 0.08 ± 0.02 0.04 ± 0.01 0.02 ± 0.01
LPS 0.05 ± 0.01 0.11 ± 0.03 0.13 ± 0.03 0.13 ± 0.04 0.12 ± 0.04 0.10 ± 0.04 0.10 ± 0.04
LPS + rhAPC 0.07 ± 0.01 0.11 ± 0.02 0.10 ± 0.01 0.08 ± 0.03 0.10 ± 0.03 0.09 ± 0.03 0.08 ± 0.03
Arterial pH
rhAPC 7.50 ± 0.01 7.47 ± 0.01 7.44 ± 0.03 7.44 ± 0.04 7.45 ± 0.03 7.49 ± 0.02 7.48 ± 0.02
LPS 7.51 ± 0.01 7.55 ± 0.01 7.54 ± 0.01 7.54 ± 0.01 7.52 ± 0.03 7.53 ± 0.03 7.53 ± 0.03
LPS + rhAPC 7.49 ± 0.02 7.54 ± 0.01* 7.51 ± 0.01 7.49 ± 0.01† 7.50 ± 0.01† 7.52 ± 0.01* † 7.51 ± 0.01†
PaCO2 (kPa)
rhAPC 33 ± 2 33 ± 1 33 ± 1 34 ± 2 35 ± 1 33 ± 1 33 ± 1
LPS 36 ± 1 35 ± 3 33 ± 1 33 ± 1 34 ± 1 34 ± 1 35 ± 1
LPS + rhAPC 36 ± 1 31 ± 2* 32 ± 1* 34 ± 2 36 ± 2† 35 ± 2† 35 ± 2†
Hemoglobin (g/dl)
rhAPC 9.1 ± 1.2 9.1 ± 1.3 9.2 ± 1.2 8.7 ± 1.0 8.9 ± 1.1 9.2 ± 1.1 9.3 ± 1.1
LPS 8.7 ± 0.7 10.4 ± 0.6* 10,3 ± 0.7* 9.6 ± 0.6* † 9.7 ± 0.7* 9.7 ± 0.6* 9.6 ± 0.7*
LPS + rhAPC 9.5 ± 0.6 10.8 ± 0.6* 10.2 ± 0.6† 9.6 ± 0.6† 9.4 ± 0.5† 9.3 ± 0.4† 9.4 ± 0.5†
Temperature (°C)
rhAPC 39.4 ± 0.1 39.4 ± 0.1 39.3 ± 0.2 39.4 ± 0.2 39.3 ± 0.2 39.2 ± 0.2 39.1 ± 0.1
LPS 39.2 ± 0.2 40.8 ± 0.3* 40.2 ± 0.2* 40.3 ± 0.2* 40.5 ± 0.2* 40.3 ± 0.3* 40.1 ± 0.2*
LPS + rhAPC 39.1 ± 0.1 41.0 ± 0.3* 40.2 ± 0.2* † 40.0 ± 0.1* † 40.0 ± 0.1* † 40.0 ± 0.2* † 39.9 ± 0.2* †
Antithrombin III plasma 
concentration (%)
rhAPC 70 ± 2 74 ± 2 70 ± 2 70 ± 3
LPS 79 ± 3 71 ± 4* 66 ± 4* † 63 ± 4* †
LPS + rhAPC 69 ± 3 69 ± 3 62 ± 3* † 58 ± 2* †
Data presented as the mean ± standard error of the mean. rhAPC, recombinant human activated protein C alone group (n = 4); LPS, 
lipopolysaccharide group (n = 8); LPS + rhAPC, rhAPC-treated LPS group (n = 9). SaO2, arterial oxygen saturation; SvO2, central venous oxygen 
saturation; DO2I, oxygen delivery index; VO2I, oxygen consumption index; Qs/Qt, venous admixture. *P < 0.05 from t = 0 hours. †P < 0.05 from t 
= 4 hours.Available online http://ccforum.com/content/12/4/R104
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the LPS group and the LPS + rhAPC group at 24 hours. When
a normal distribution of data could not be demonstrated, the
Mann–Whitney U test was employed to compare the LPS and
the LPS + rhAPC groups. Missing values were not replaced
by imputation. P < 0.05 was considered statistically signifi-
cant.
Results
One sheep from the LPS group died of respiratory failure after
20 hours, and one animal from the LPS + rhAPC group died
of circulatory failure after 16 hours. None of the animals suf-
fered from bleeding. As displayed in Figure 1 and Table 1, the
pulmonary hemodynamic and volumetric parameters remained
unchanged with rhAPC alone. The infusion of rhAPC, how-
ever, decreased the LPS-induced elevations of PAP, Pmo and
PVRIdwn with intergroup differences (P < 0.05). The PVRIup
and the PVRI also declined with rhAPC treatment (P < 0.05),
but with no intergroup differences (P = 0.63 and P = 0.17).
The pulmonary arterial occlusion pressure remained
unchanged. Infusion of LPS led to rapid and sustained rises in
the PVPI (P < 0.05) and the EVLWI (P < 0.001), which were
both antagonized by infusion of rhAPC (P < 0.001) with differ-
ences between the groups (P < 0.01 and P < 0.05 for PVPI
and EVLWI, respectively).
The intrathoracic blood volume index, pulmonary blood volume
index, right ventricle end-diastolic volume and right ventricle
ejection fraction did not change significantly between the
groups (data not shown). Moreover, infusion of rhAPC had no
significant effects on the LPS-induced changes in right atrial
pressure, heart rate, mean systemic arterial pressure, systemic
vascular resistance index, CI, stroke volume index, LAP, and
left and right ventricle stroke work indices in any of the groups
(Table 1).
Figure 2 and Table 2 show no changes in oxygenation after
rhAPC alone. Infusion of LPS decreased the PaO2 abruptly in
concert with a rise in the alveolar–arterial oxygen tension dif-
ference (P < 0.01), which improved significantly in response
to administration of rhAPC (P < 0.05). Mixed venous oxygen
saturation and PaCO2 increased in the LPS + rhAPC group (P
< 0.05), but with no significant intergroup differences. Expo-
sure to LPS increased the body temperature and oxygen deliv-
ery index (P < 0.001), and tended to increase the oxygen
consumption index (P = 0.051). Treatment with rhAPC, how-
ever, had no significant effect on these changes. The hemo-
globin concentration initially increased during LPS infusion (P
< 0.001) and decreased during rhAPC treatment (P < 0.001),
but with no significant intergroup difference.
With rhAPC alone, the protein C and antithrombin III levels
remained unchanged while the International Normalized Ratio
and the fibrinogen level increased by nearly 10% (P < 0.05;
Table 2 and Figure 3). Infusion of LPS reduced protein C by
49% and 33% in the LPS group and in the LPS + rhAPC
group, respectively (P < 0.001), with an intergroup difference
at 24 hours (P  < 0.05). In both LPS groups, fibrinogen
decreased to a nadir approximately 30% below baseline and
then increased in rhAPC-treated animals (P < 0.05), but with
no difference between groups (P = 0.08). The antithrombin III
concentration fell and the International Normalized Ratio
increased gradually (P < 0.001), with no significant intergroup
difference.
As depicted in Figure 3, TNFα peaked at 12 hours (P < 0.05)
in the LPS group and subsequently declined to significantly
above baseline at 24 hours. In the LPS + rhAPC group, TNFα
decreased beyond 4 hours, with an intergroup difference after
12 hours (P < 0.05).
Figure 2
Changes in arterial oxygenation in awake, endotoxemic sheep Changes in arterial oxygenation in awake, endotoxemic sheep. rhAPC, recombinant human activated protein C alone group (n = 4); LPS, lipopoly-
saccharide group (n = 8); LPS + rhAPC, rhAPC-treated LPS group (n = 9). Data presented as the mean ± standard error of the mean. PaO2, arterial 
oxygen partial pressure; AaPO2, alveolar–arterial oxygen tension difference. †P < 0.05 between the LPS and the LPS + rhAPC groups; ‡P < 0.05 
from t = 0 hours in the LPS group; §P < 0.05 from t = 4 hours in the LPS group; *P < 0.05 from t = 0 hours in the LPS + rhAPC group; #P < 0.05 
from t = 4 hours in the LPS + rhAPC group.Critical Care    Vol 12 No 4    Waerhaug et al.
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In lung tissue from sheep exposed to LPS, we found a 65% to
75% reduction of the α and ε isoforms of PKC in the cytosolic
fraction of tissue homogenate, as compared with samples
from sham-operated animals (P < 0.05; Figure 4). In the LPS
+ rhAPC group, the cytosolic fraction of PKCα and PKCε
remained significantly higher than in the LPS group (P < 0.05).
Table 3 presents the individual scores constituting the lung
injury score. In animals exposed to LPS the lung injury score
was elevated (P < 0.01), but the score was 34% lower in the
LPS + rhAPC group (P < 0.01). Figure 5 shows photomicro-
graphs of typical lung sections, with low-power fields to the
left. The marked squares are displayed as high-power fields to
the right. In sheep subjected to rhAPC alone (Figure 5a),
nearly normal histological conditions were found. Lungs
exposed to LPS (Figure 5b) displayed edematous, expanded
and disrupted alveoli with interstitial neutrophile infiltration. All
the latter changes were less pronounced in the LPS + rhAPC
group (Figure 5c).
Discussion
The present study demonstrates that continuously infused
rhAPC alleviates endotoxin-induced lung injury in awake
sheep. The enhanced EVLWI, a major characteristic of this
model, decreased significantly upon administration of rhAPC.
Dampening of pulmonary vascular pressures in parallel with a
reduction of PVRIdwn and improvement of gas exchange con-
certed the reduction of EVLWI. Administration of rhAPC also
prevented elevation of the plasma concentration of TNFα, and
normalized the plasma level of protein C. Moreover, rhAPC
reduced the PVPI and counteracted the depletion of the α and
ε isoforms of PKC from the cytosolic fraction of lung tissue
homogenate, simultaneously maintaining pulmonary histologi-
cal integrity.
Infusion of LPS provides a possibility of mimicking human ALI
in different species, including sheep [22,23]. The fact that two
animals died during the course of the 24-hour experiments
illustrates the severity of this lung injury model, which is asso-
ciated with a lethality of nearly 30% without supportive therapy
Figure 3
Changes in coagulation and inflammatory markers in awake, endotoxemic sheep Changes in coagulation and inflammatory markers in awake, endotoxemic sheep. rhAPC, recombinant human activated protein C alone group (n = 
4); LPS, lipopolysaccharide group (n = 8); LPS + rhAPC, rhAPC-treated LPS group (n = 9). Data presented as the mean ± standard error of the 
mean. INR, International Normalized Ratio. †P < 0.05 between the LPS and the LPS + rhAPC groups; ‡P < 0.05 from t = 0 hours in the LPS group; 
§P < 0.05 from t = 4 hours in the LPS group; *P < 0.05 from t = 0 hours in the LPS + rhAPC group; #P < 0.05 from t = 4 hours in the LPS + 
rhAPC group; &P < 0.05 from t = 0 hours in the rhAPC group.Available online http://ccforum.com/content/12/4/R104
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[7,25]. The LPS-induced increase in the EVLWI and the
changes in lung hemodynamics are consistent with observa-
tions made in previous studies employing the same dose of
endotoxin over 24 hours [24,25]. Despite the fact that we
treated sheep with rhAPC specifically designed for the human,
it markedly reversed the LPS-induced procoagulant and proin-
flammatory states. This might indicate a degree of cross-reac-
tion between the inflammation and the coagulation systems of
the two species, in agreement with other recent investigations
[20,21].
Following administration of rhAPC dosed as recommended for
patients with severe sepsis [17], we noticed that the
enhanced EVLWI declined towards baseline immediately after
commencement of the drug. Furthermore, the PAP, Pmo and
PVRIdwn, all rising during infusion of LPS, decreased markedly
during rhAPC infusion. We believe that the reduction of
PVRIdwn prompted the falls in PAP and Pmo, and therefore
partly explains the rhAPC-induced reduction of EVLWI. The
decrease in PAP is consistent with recent findings of May-
bauer and colleagues, reporting that rhAPC, administered 1
hour subsequent to smoke inhalation and sepsis, improves
pulmonary function in sheep [20]. Correspondingly, Wang
and colleagues, also using an ovine model of severe sepsis,
noticed that rhAPC antagonizes lactic acidosis, derangements
of hemodynamics and gas exchange as well as coagulation
abnormalities 2 hours subsequent to peritoneal instillation of
feces [21]. The latter investigators also observed that rhAPC
reduces the lung wet/dry weight ratio.
In the present study, we display the course of changes in
EVLWI over 24 hours. Not obvious to us, however, was
whether the decrease in EVLWI was a result of reduced Pmo,
of reduced permeability, or of both reductions combined.
Relating EVLWI to the lung blood volume, the PVPI suppos-
edly indicates evolvement of edema due to increased leaki-
ness of the lung vasculature [29,31,32]. We observed that
PVPI increased and stabilized at a ratio of nearly 2.5 in the LPS
group (Figure 1), which is slightly higher than that noticed by
Kuzkov and colleagues in nonsurvivors of severe sepsis and
ALI [31]. Moreover, the ratio of approximately 1.5 that we
observed in the LPS + rhAPC group was not significantly dif-
ferent from baseline. Although the PVPI is not unequivocally
accepted as a measure of vascular permeability [33], this find-
ing could indicate an APC-dependent preservation of vascular
integrity.
Deterioration of gas exchange accompanied the accumulation
of extravascular lung water, as shown in previous investiga-
tions of ALI after LPS treatment in sheep [5,23,34]. The
impaired oxygenation (Figure 2) improved significantly in the
LPS + rhAPC group in parallel with a normalization of PaCO2,
consistent with recent animal reports [20,21] and with the
PROWESS study [17]. The latter workers demonstrated
Figure 4
Protein kinase C α and ε isoforms in the cytosole fraction of lungs from  sheep Protein kinase C α and ε isoforms in the cytosole fraction of lungs from 
sheep. Western blots and densitometry tracings of protein kinase C 
(PKC)α and PKCε in the cytosole fraction of lungs from sheep. Sham, 
sham-operated group (n = 4); LPS, lipopolysaccharide group (n = 8); 
LPS + rhAPC, rhAPC-treated LPS group (n = 9). †P < 0.05 between 
the LPS and the LPS + rhAPC groups; ‡P < 0.05 between the LPS 
and the sham groups. Data presented as the percentage of the mean 
densitometry value in sham-operated sheep (n = 4).Critical Care    Vol 12 No 4    Waerhaug et al.
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Table 3
Lung injury score in instrumented awake sheep
Variable Edema Neutrophil infiltration Hemorrhage Epithelial desquamation Hyaline membranes Lung injury score
rhAPC 1.3 (1.0 to 2.0) 0.5 (0.0 to 2.0) 1.0 (0.0 to 3.0) 0.5 (0.0 to 1.0) 0.0 (0.0 to 1.0) 3.8 (2.0 to 6.5)
LPS 2.0 (1.0 to 3.0) 2.5 (0.5 to 3.5)* 0.8 (0.0 to 2.0) 1.0 (0.5 to 4.0)* 1.0 (0.0 to 2.0)* 6.8 (2.5 to 11.5)*
LPS + rhAPC 1.0 (0.5 to 2.0)† 1.0 (0.0 to 2.0)† 1.0 (0.0 to 2.0) 1.0 (0.5 to 2.0) 0.5 (0.0 to 2.0) 4.5 (1.5 to 8.5)†
Data presented as the median (minimum to maximum). rhAPC, recombinant human activated protein C alone group (n = 4); LPS, 
lipopolysaccharide group (n = 8); LPS + rhAPC, rhAPC-treated LPS group (n = 9). The histological markers of lung injury are scored on a scale 
from zero to four. *P < 0.05 between the LPS and the rhAPC groups. †P < 0.05 between the LPS and the LPS + rhAPC groups.
Figure 5
Photomicrographs of H&E-stained ovine right lung lower lobe sections from experiments over 24 hours Photomicrographs of H&E-stained ovine right lung lower lobe sections from experiments over 24 hours. Left: sections magnified ×100. Right: fields 
limited by squares are magnified ×400. (a) Sheep exposed to recombinant human activated protein C (rhAPC) alone, displaying no gross changes 
from normal. (b) Sheep exposed to intravenous infusion of lipopolysaccharide (LPS). Hyperemia and intravascular accumulation and extravasation of 
neutrophils (arrows) are accompanied by interstitial edema and thickening of interalveolar and interlobular (ias and ils) septa as well as injury to the 
alveolar lining with formation of hyaline membranes (hm). (c) Sheep treated with infusion of rhAPC from 4 hours after the commencement of LPS. 
Interlobular and interalveolar septa are predominantly infiltrated with lymphocytes (arrows) and interalveolar septa have returned to nearly normal 
thickness. Hyaline membranes are partly dissolved.Available online http://ccforum.com/content/12/4/R104
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faster resolution of cardiovascular and respiratory dysfunc-
tions in rhAPC-treated patients [18].
In the present investigation, administration of LPS led to deple-
tion of protein C and fibrinogen. The increase in the plasma
concentration of fibrinogen during treatment with rhAPC is
consistent with the findings of Taylor and colleagues, who
concluded that APC prevents both the coagulopathy and the
lethal effects of infusion of live E. coli in baboons [19]. Moreo-
ver, the better maintained concentration of protein C following
administration of rhAPC agrees with corresponding findings of
Wang and colleagues in septic sheep treated with rhAPC
[21]. According to a recent investigation, a decrease in protein
C is a regular finding in patients with severe sepsis and an
early and independent predictor of sepsis mortality [35].
In the present study, the enhanced plasma concentration of
TNFα and the depletion of PKCα and PKCε from the cytosolic
fraction of lung tissue homogenate after LPS, as previously
reported [24], vanished during treatment with rhAPC. Moreo-
ver, histological examination revealed less inflammatory
changes in rhAPC-treated endotoxemic animals, as evaluated
by reduced neutrophil infiltration and decreased edematous
changes in lung tissue. Our results agree with an investigation
in endotoxemic rats demonstrating an APC-induced decrease
in the lung wet/dry weight ratio in parallel with reduced accu-
mulation of leukocytes in the lungs and a fall in the plasma con-
centration of TNFα [12,36]. In volunteers subjected to
instillation of LPS into the airways, Nick and colleagues dem-
onstrated increased neutrophil migration into the air spaces
that was prevented with rhAPC [13]. The latter observation is
consistent with our observation that the lung injury score
decreased mainly as a result of less neutrophils in the lung
sections of rhAPC-treated endotoxemic sheep. Moreover, Kir-
schenbaum and colleagues noticed that rhAPC prevents neu-
trophil-platelet interaction with endothelial cells from healthy
subjects, when stimulated with plasma from patients in septic
shock. These authors suggested that rhAPC preserves micro-
vascular patency in severe sepsis [37], which is consistent
with the regression of LPS-induced increases in the PVPI and
the EVLWI after infusion of rhAPC in the present study. In this
study, plasma concentrations of TNFα peaked 12 hours after
administration of LPS. The sustained high levels of TNFα in the
LPS group is consistent with observations in patients with
sepsis, in whom persistent high levels of TNFα correlates with
severity of illness [38].
Some limitations must be taken into account when evaluating
the results of this study. Firstly, coagulation and inflammatory
markers have in total 17% missing values that reduce the
power of the study as these variables are concerned. Sec-
ondly, we used human kits for determination of TNFα and for
coagulation tests, due to the lack of kits specifically designed
for sheep. As evolutionary old systems, however, both the
innate immune system and the coagulation system expectedly
have a high degree of cross-reactivity in mammals [39]. The
change in plasma concentration of TNFα during exposure to
LPS is consistent with previously reported observations from
our group where we used human antibodies in combination
with the same automated system for cytokine analysis [24].
Conclusion
The present study demonstrates that infused rhAPC amelio-
rates ovine LPS-induced ALI, as indicated by a decrease in the
EVLWI associated with improvements of gas exchange and
markers of inflammation and coagulation. We suggest that
treatment with rhAPC reduces lung fluid extravasation by
dampening both the pressure and the permeability of the lung
microvasculature. Further studies are warranted to determine
whether these beneficial effects also apply in patients suffer-
ing from sepsis – and in patients from nonsepsis-induced ALI.
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